SAN DIEGO--(BUSINESS WIRE)--Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today the full-scale launch of Kurin Jet, which has joined the Kurin Lock family. The original member of the Kurin Lock family, now named the Kurin Flash, is the market-leading product in this space. The Kurin Jet provides a significant technological advancement over Kurin Flash.
“We had earlier announced a limited commercial release and have been thrilled with responses from customers using Jet,” said Bob Rogers, CEO of Kurin, Inc. “Feedback from those using Jet has been very positive with clinicians amazed at how fast Jet works, and they appreciate the greater control it allows. Automated manufacturing has started, and we are now able to provide this next generation product more widely. Kurin Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”
Kurin Flash became the market-leading product because of its small size, small amount of blood required and ease of use. Compliance is the key to improving clinical outcomes and the increased speed and control make Kurin Jet even easier to use, helping hospitals address this important clinical problem.
Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Like the Kurin Flash, Kurin Jet passively sidelines potential contaminants during blood culture collection. Kurin Flash and Kurin Jet both provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Flash and Kurin Jet give clinicians the tools they need to address these problems.
About Kurin, Inc.
Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.